First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expres...
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
About this item
Full title
Author / Creator
Angevin, Eric , Isambert, Nicolas , Trillet-Lenoir, Véronique , You, Benoit , Alexandre, Jérôme , Zalcman, Gérard , Vielh, Philippe , Farace, Françoise , Valleix, Fanny , Podoll, Thomas , Kuramochi, Yu , Miyashita, Itaru , Hosono, Osamu , Dang, Nam H , Ohnuma, Kei , Yamada, Taketo , Kaneko, Yutaro and Morimoto, Chikao
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
YS110 is a humanised IgG1 monoclonal antibody with high affinity to the CD26 antigen. YS110 demonstrated preclinical anti-tumour effects without significant side effects.
Methods:
This FIH study was designed to determine the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) to assess the tolerance, pharmacokineti...
Alternative Titles
Full title
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5418443
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5418443
Other Identifiers
ISSN
0007-0920,1532-1827
E-ISSN
1532-1827
DOI
10.1038/bjc.2017.62
